AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 09/01/20

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2020. The presentation will begin at 4:15 PM Eastern Time and a live webcast will be acc...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patc...

WARSAW, Ind., Aug. 12, 2020 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, is pleased to announce the appointment of Jeff George, global healthcare executive and investor, to the company’s board of directors, effective August 12, 2020. ...

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2020 Earnings Conference Call August 06, 2020, 08:30 ET Company Participants Anastasios Konidaris - EVP & CFO Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Joseph Todisco -...

Image source: The Motley Fool. Amneal Pharmaceuticals, Inc.   (NYSE: AMRX) Q2 2020 Earnings Call Aug 6, 2020 , 8:30 a.m. ET Operator Continue reading

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

  ‒ Q2 2020 Net Revenue of $465 million; GAAP Net Loss of $(12) million; Diluted Loss per Share of $(0.08) ‒ ‒ Q2 2020 Adjusted Net Income (1) of $38 million; Adjusted EBITDA (1) of $101 million; Adjusted Diluted EPS (1) of $0.13‒ ‒ M...

Eastman Kodak Co.’s (NASDAQ: KODK) stock tripled following the announcement that the once-bankrupt company had received a $765 million loan from the Trump administration to fund a pharmaceutical ingredients company. A MarketWatch article written by Jaimy Lee noted that “Kodak, wh...

BRIDGEWATER, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Cosette Pharmaceuticals, Inc. (“Cosette” or the “Company”), a privately held specialty generic pharmaceutical company primarily focused on extended topical and suppository products, announced today the appointm...

DBV Technologies Reports Positive Extension Study Results DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Pea...